SPOTLIGHT: FDA gives nod to new Plavix dose


Sanofi-Aventis and Bristol-Myers Squibb announced that they'd nabbed FDA approval for a new 300 mg strength of the anti-clotting drug Plavix, for use as a loading dose when heart patients come into the ER. Release

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.